摘要
据估计,小细胞肺癌在所有肺癌患者中占1/6。小细胞肺癌通常被诊断为癌症晚期。不幸的是,在这个阶段,预后很糟糕。贝伐单抗是一种针对血管内皮生长因子的单克隆抗体,它能抑制恶性肿瘤的血管新生。尽管贝伐单抗被批准用于非小细胞肺癌的第一线药物,但它在小细胞肺癌的应用有了第一次报道。在这篇综述中,我们总结了贝伐单抗在小细胞肺癌患者应用中所有可行的数据。最后对未来的方向展开了讨论。
关键词: 贝伐单抗,肺癌,维护,小细胞
Current Cancer Drug Targets
Title:Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
Volume: 16 Issue: 3
Author(s): Giandomenico Roviello and Daniele Generali
Affiliation:
关键词: 贝伐单抗,肺癌,维护,小细胞
摘要: It was estimated that small cell lung cancer (SCLC) accounts for about one Sixth of all lung cancer cases. Patients with SCLC are usually diagnosed in advanced stage of disease. Unfortunately at this stage, prognosis is very poor. Bevacizumab is a monoclonal antibody against VEGF, which inhibits the angiogenesis in malignant tumors. Although Bevacizumab has been approved for firstline use in advanced non-SCLC, the first report has been available for its use in SCLC. In this review, we summarized all available data on the use of Bev in SCLC patients. Finally, future directions are discussed.
Export Options
About this article
Cite this article as:
Giandomenico Roviello and Daniele Generali , Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?, Current Cancer Drug Targets 2016; 16 (3) . https://dx.doi.org/10.2174/1568009616666151106120716
DOI https://dx.doi.org/10.2174/1568009616666151106120716 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology Synergistic Activities of a Silver(I) Glutamic Acid Complex and Reactive Oxygen Species (ROS): A Novel Antimicrobial and Chemotherapeutic Agent
Current Medicinal Chemistry Glycyrrhetinic Acid and Its Derivatives: Anti-Cancer and Cancer Chemopreventive Properties, Mechanisms of Action and Structure- Cytotoxic Activity Relationship
Current Medicinal Chemistry Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Hybrid Molecules Incorporating Natural Products: Applications in Cancer Therapy, Neurodegenerative Disorders and Beyond
Current Medicinal Chemistry Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
Current Drug Targets Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy
Current Cancer Drug Targets Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery Development Course and an Application Strategy for Induced Pluripotent Stem Cells in Regenerative Medicine
Current Stem Cell Research & Therapy Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment
Combinatorial Chemistry & High Throughput Screening Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Drp1 in Ischemic Neuronal Death: An Unusual Suspect
Current Medicinal Chemistry